Overview
- Cynata Inc is a California registered company with rights to certain novel stem cell technology licensed from Wisconsin University Alumni Research Foundation (WARF)
- Cynata is 33% owned by ECQ through investment of $1m in the company to date
- ECQ has an option to acquire all remaining shares in Cynata:
Conditional upon ECQ shareholder approval+ compliance with laws/ASX + recompliance with Chapters 1 & 2
Consideration: 200m ECQ shares (currently 636m out)
11 shareholders will hold 23.9% of ECQ (largest with 5.7%)
- Upon completion of the potential acquisition, ECQ will be re-purposed as a biotechnology company with Cynata’s technology as its chief asset
To view Presentation please download PDF below:
